These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 20729919)

  • 1. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
    Chen KF; Liu CY; Lin YC; Yu HC; Liu TH; Hou DR; Chen PJ; Cheng AL
    Oncogene; 2010 Nov; 29(47):6257-66. PubMed ID: 20729919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A.
    Chen KF; Yu HC; Liu CY; Chen HJ; Chen YC; Hou DR; Chen PJ; Cheng AL
    Mol Cancer Ther; 2011 May; 10(5):892-901. PubMed ID: 21393428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
    Yu HC; Chen HJ; Chang YL; Liu CY; Shiau CW; Cheng AL; Chen KF
    Biochem Pharmacol; 2013 Feb; 85(3):356-66. PubMed ID: 23178652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
    Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.
    Liu CY; Shiau CW; Kuo HY; Huang HP; Chen MH; Tzeng CH; Chen KF
    Haematologica; 2013 May; 98(5):729-38. PubMed ID: 22983581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC; Chen KC; Chen CC; Cheng AL; Chen KF
    Oral Oncol; 2012 Jul; 48(7):585-93. PubMed ID: 22342571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
    Yu HC; Hung MH; Chen YL; Chu PY; Wang CY; Chao TT; Liu CY; Shiau CW; Chen KF
    Cell Death Dis; 2014 Jul; 5(7):e1359. PubMed ID: 25077545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
    Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.
    Yu HC; Hou DR; Liu CY; Lin CS; Shiau CW; Cheng AL; Chen KF
    PLoS One; 2013; 8(2):e55705. PubMed ID: 23383345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
    Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
    Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
    Chen KF; Yeh PY; Hsu C; Hsu CH; Lu YS; Hsieh HP; Chen PJ; Cheng AL
    J Biol Chem; 2009 Apr; 284(17):11121-33. PubMed ID: 19261616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A.
    Huang CY; Wei CC; Chen KC; Chen HJ; Cheng AL; Chen KF
    Cancer Lett; 2012 Apr; 317(1):9-15. PubMed ID: 22085493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
    Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of CIP2A in the antitumor effect of bortezomib in colon cancer.
    Ding Y; Wang Y; Ju S; Wu X; Zhu W; Shi F; Mao L
    Mol Med Rep; 2014 Jul; 10(1):387-92. PubMed ID: 24789441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib congeners induce apoptosis of hepatocellular carcinoma via CIP2A inhibition.
    Hou DR; Huang AC; Shiau CW; Wang CY; Yu HC; Chen KF
    Molecules; 2013 Dec; 18(12):15398-411. PubMed ID: 24335617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
    Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
    Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
    Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
    Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.
    Chao TT; Wang CY; Chen YL; Lai CC; Chang FY; Tsai YT; Chao CH; Shiau CW; Huang YC; Yu CJ; Chen KF
    Oncotarget; 2015 Feb; 6(4):2164-79. PubMed ID: 25537503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.